Current Report Filing (8-k)
June 20 2019 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2019
Aileron Therapeutics, Inc.
(Exact Name of Company as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-38130
|
|
13-4196017
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
490 Arsenal Way, Suite 210
Watertown, MA
|
|
02472
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 995-0900
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
ALRN
|
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.07 Submission of Matters to a Vote of Security Holders.
Aileron Therapeutics, Inc. (the Company) held its Annual Meeting of Stockholders on June 19, 2019. The following is a summary of the matters
voted on at that meeting.
|
(a)
|
The stockholders of the Company elected Nolan Sigal, M.D. as Class II director for a three-year term
ending at the annual meeting of stockholders to be held in 2022. The results of the stockholders vote with respect to the election of the Class II director were as follows:
|
|
|
|
|
|
|
|
Name
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Nolan Sigal, M.D.
|
|
13,935,730
|
|
308,875
|
|
4,155,825
|
|
(b)
|
The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Companys
independent registered public accounting firm for the fiscal year ending December 31, 2019. The results of the stockholders vote with respect to such ratification were as follows:
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
18,061,010
|
|
338,316
|
|
1,104
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Aileron Therapeutics, Inc.
|
|
|
|
Date: June 20, 2019
|
|
By:
|
|
/s/ Donald Dougherty
|
|
|
|
|
Donald Dougherty
|
|
|
|
|
Chief Financial Officer
|
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Apr 2023 to Apr 2024